{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005368","form_type":"8-K","ticker":"PTIX","cik":"0001022899","company_name":"Protagenic Therapeutics, Inc.new","filed_at":"2025-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.169712+00:00","generated_at":"2026-05-23T10:53:02.822711+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagenic shareholders approve reverse stock split at ratio 1:10 to 1:20","bullets":["Special Meeting held April 18, 2025; 4,049,963 shares present out of 7,241,443 entitled.","Reverse split proposal passed: 3,560,865 for, 333,824 against, 155,274 abstain.","Board authorized to choose exact ratio between 1:10 and 1:20 and timing before Jan 31, 2026.","Adjournment proposal also approved: 3,552,086 for, 336,677 against, 161,200 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005368","json":"https://secwatch.observer/filing/0001641172-25-005368.json","markdown":"https://secwatch.observer/filing/0001641172-25-005368.md","text":"https://secwatch.observer/filing/0001641172-25-005368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225005368/0001641172-25-005368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022899/000164117225005368/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T10:53:02.822711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}